HealthEquity (NASDAQ:HQY) Given New $110.00 Price Target at Barrington Research

HealthEquity (NASDAQ:HQY) had its target price lowered by analysts at Barrington Research from $125.00 to $110.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Barrington Research’s price objective would indicate a potential upside of 38.65% from the company’s previous close.

HQY has been the topic of several other research reports. Royal Bank Of Canada lowered their price target on HealthEquity from $110.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday. Raymond James Financial set a $100.00 price objective on shares of HealthEquity in a report on Tuesday, February 17th. Wall Street Zen upgraded shares of HealthEquity from a “hold” rating to a “buy” rating in a research note on Monday, January 19th. Barclays dropped their target price on shares of HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, February 18th. Finally, UBS Group set a $110.00 price target on HealthEquity in a research report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $109.79.

HealthEquity Stock Down 0.1%

Shares of NASDAQ:HQY traded down $0.06 on Wednesday, reaching $79.34. The company had a trading volume of 654,862 shares, compared to its average volume of 1,024,710. The stock has a market capitalization of $6.78 billion, a P/E ratio of 36.37, a P/E/G ratio of 0.98 and a beta of 0.26. The stock has a 50-day moving average price of $81.30 and a 200 day moving average price of $90.27. HealthEquity has a twelve month low of $72.76 and a twelve month high of $116.65. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 0.46.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, March 17th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.05. HealthEquity had a return on equity of 12.94% and a net margin of 14.86%.The business had revenue of $334.59 million for the quarter, compared to analyst estimates of $332.48 million. The company’s quarterly revenue was up 7.3% on a year-over-year basis. On average, equities analysts expect that HealthEquity will post 2.32 EPS for the current year.

Insider Buying and Selling

In related news, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $94.72, for a total transaction of $142,080.00. Following the completion of the transaction, the executive vice president owned 73,979 shares in the company, valued at $7,007,290.88. This trade represents a 1.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elimelech Rosner sold 10,959 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $95.45, for a total value of $1,046,036.55. Following the completion of the sale, the executive vice president directly owned 45,742 shares in the company, valued at approximately $4,366,073.90. This represents a 19.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its position in HealthEquity by 61.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 14,491 shares of the company’s stock worth $1,328,000 after acquiring an additional 5,541 shares during the last quarter. Montanaro Asset Management Ltd boosted its stake in HealthEquity by 13.1% in the fourth quarter. Montanaro Asset Management Ltd now owns 37,200 shares of the company’s stock worth $3,408,000 after purchasing an additional 4,300 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of HealthEquity during the fourth quarter worth $219,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of HealthEquity by 2,476.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 438 shares of the company’s stock worth $40,000 after purchasing an additional 421 shares during the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of HealthEquity by 16.9% in the fourth quarter. Pacer Advisors Inc. now owns 13,427 shares of the company’s stock valued at $1,230,000 after buying an additional 1,937 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting HealthEquity

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: Q4 results beat estimates and management raised fiscal‑2027 guidance — Company reported record revenue, higher net income and new HSAs from sales, and lifted its outlook, which supports upside to earnings and cash flow expectations. HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026
• Positive Sentiment: Quarterly earnings and revenue topped analyst estimates (EPS $0.95 vs. consensus ~$0.90; revenue ~$334.6M vs. ~$332.5M), reinforcing the beat-and-raise narrative and validating margin improvement. HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Analyst upgrade: Seeking Alpha upgraded HQY citing improved cash economics and better free‑cash‑flow conversion, which can support valuation multiple expansion. HealthEquity: Attractive Given Improved Cash Economics (Rating Upgrade)
• Neutral Sentiment: Earnings call and transcript coverage provide detail on HSA growth, margin drivers and FY27 assumptions — useful for modeling but largely confirm the press release takeaways. HealthEquity (HQY) Q4 2026 Earnings Transcript
• Neutral Sentiment: Additional transcripts and analyst pre‑earnings coverage summarize key metrics and consensus expectations; informative for traders but not new directional catalysts. HealthEquity, Inc. (HQY) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Royal Bank of Canada cut its price target from $110 to $100 while keeping an Outperform rating — a reduction in analyst price target can temper some upside expectations and weigh on near‑term sentiment. Benzinga: RBC Lowers Price Target on HealthEquity

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.